ArticleTherapeutic advances in hematology2024

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Juan Carlos Caballero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.